Supplementation therapy with Antithrombin Drugs in the Combined Treatment of Sepsis
https://doi.org/10.15360/1813-9779-2019-5-34-43
Abstract
Purpose — to assess the efficacy of supplementation therapy for antithrombin deficiency in the combined treatment of sepsis.
Materials and methods. A prospective-retrospective study of the efficacy of supplementation therapy for antithrombin deficiency during sepsis was carried out; 90 patients were examined. The patients were split into two groups whether antithrombin deficiency correction was or was not undertaken. The composite outcome — the incidence of cardiovascular complications as of day 28 from the therapy commencement — was chosen as the primary endpoint of the study. The secondary endpoints of the study were prevalence of adverse events as of day 28 from the therapy commencement and 180-day mortality.
Results. There was no difference between the groups either in respect of 28-day mortality or composite outcome. Analysis of secondary endpoints revealed that in the group of patients who received antithrombin supplementation therapy, the risk of development of an acute renal injury was significantly lower on day 28 and 180 from therapy commencement: OR 3.5 [95% CI 1.05–11.66] at P=0.04 and OR 2.92 [95% CI 1.02–8.31] at P=0.045, respectively.
Conclusion. Correction of antithrombin level to activity level ‘over 61%’ is associated with decreased incidence degree III acute kidney failure (KDIGO).
About the Authors
I. V. Redkin
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
61/2 Shchepkin Str., Moscow 129110, Russia
A. F. Lopatin
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
61/2 Shchepkin Str., Moscow 129110, Russia
A. G. Yavorovskiy
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
8 Trubetskaya Str., Bldg. 2, 119991 Moscow, Russia
V. V. Likhvantsev
M. F. Vladimirsky Moscow Regional Research Clinical Institute,
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
61/2 Shchepkin Str., Moscow 129110, Russia
8 Trubetskaya Str., Bldg. 2, 119991 Moscow, Russia
References
1. Shankar-Hari M., Phillips G.S., Levy M.L., Seymour C.W. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 15 (8): 775–787. DOI: 10.1001/jama.2016.0289.
2. Marchioni A, Fantini R, Antenora F, Clini E, Fabbri L. Chronic critical illness: the price of survival. European journal of clinical investigation. 2015; 45 (12): 1341–1349. DOI: 10.1111/eci.12547
3. Angus D.C., van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013; Aug 29. 369 (9): 840–851 DOI: 10.1056/NEJMra1208623
4. Cohen J., Vincent J-L., Adhikari N.K.J., Machado F.R., Angus D.C., Calandra T. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015; 15: 581–614. DOI: 10.1016/S1473-3099 (15)70112-X
5. Vincent J.L. , Marshall J.C., Namendys-Silva S.A. , François B. , Martin-Loeches I., Lipman J , Reinhart K , Antonelli M , Pickkers P , Njimi H , Jimenez E , Sakr Y. Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir. Med. 2014; 2: 380–386. DOI: 10.1016/S2213-2600 (14)70061-X
6. Hayakawa M, Kudo D, Saito S, Uchino S. Antithrombin supplementation and mortality in sepsis-induced disseminated intravascular coagulation: a multicenter retrospective observational study. Shock. 2016; 46 (6): 623–631.DOI: 10.1097/SHK.0000000000000727
7. Hunt B.J. Bleeding and coagulopathies in critical care. N Engl J Med. 2014; 370 (9): 847–859. DOI: 10.1056/NEJMra1208626
8. Okamoto K., Tamura T., Sawatsubashi Y. Sepsis and disseminated intravascular coagulation. Journal of Intensive Care.2016; 4: 23. DOI: 10.1186/s40560-016-0149-0
9. Opal S.M., Kessler C.M., Roemisch J., Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med. 2002; 30 (5): 325-331. DOI: 10.1097/00003246-200205001-00024
10. Aibiki M., Fukuoka N., Umakoshi K., Ohtsubo S., Kikuchi S. Serum albumin levels anticipate antithrombin III activities before and after antithrombin III agent in critical patients with disseminated intravascular coagulation. Shock. 2007; 27 (2): 139–144. DOI: 10.1097/01.shk.0000239762.90335.68
11. Sié P., Letrenne E., Caranobe C., Genestal M., Cathala B., Boneu B. Factor II related antigen and antithrombin III levels as inDICators of liver failure in consumption coagulopathy. Thromb Haemost. 1982; 218–220. PMID: 6810490
12. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008; 34 (5): 459–468. DOI: 10.1055/s-0028-1092876
13. Baudo F., Caimi T.M., de Cataldo F., Ravizza A., Arlati S, Casella G., Carugo D., Palareti G., Legnani C., Ridolfi L., Rossi R., D’Angelo A., Crippa L., Giudici D., Gallioli G., Wolfler A., Calori G. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998; 24 (4): 336–342. PMID: 9609411, DOI: 10.1007/s001340050576
14. Eisele B., Lamy M., Thijs L.G., Keinecke H.O., Schuster H.P., Matthias F.R., Fourrier F., Heinrichs H., Delvos U. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, doubleblind multicenter trial plus a meta-analysis on all randomized, placebocontrolled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998; 24 (7): 663–672. PMID: 9722035, DOI: 10.1007/s001340050642
15. Gonano C., Sitzwohl C., Meitner E., Weinstabl C., Kettner S.C. Fourday antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Crit Care. 2006; 6 (10): 160.
16. Inthorn D., Hoffmann J.N., Hartl W.H., Muhlbayer D., Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock. 1997; 8 (5): 328–334. PMID: 9361342, DOI: 10.1097/00024382-199711000-00003
17. Kienast J., Juers M., Wiedermann C.J., Hoffmann J.N., Ostermann H. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006; 4 (1): 90–97. DOI: 10.1111/j.1538-7836.2005.01697.x
18. Warren B.L., Eid A., Singer P., Pillay S.S., Carl P., Novak I., Chalupa P., Atherstone A., Pénzes I., Kübler A., Knaub S., Keinecke H.O., Heinrichs H., Schindel F., Juers M., Bone R.C., Opal S.M.; KyberSept Trial Study Group.Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286: 1869–1878. PMID: 11597289, DOI: 10.1001/jama.286.15.1869
19. Hayakawa M, Yamakawa K, Kudo D, Ono K. Optimal antithrombin activity threshold for initiating antithrombin supplementation in patients with sepsis-induced disseminated intravascular coagulation: a multicenter retrospective observational study. Clinical and Applied Thrombosis/Hemostasis. 2018; 24 (6): 874–883. DOI: 10.1177/1076029618757346
20. Gando S., Saitoh D., Ishikura H., Ueyama M., Otomo Y., Oda S., Kushimoto S., Tanjoh K., Mayumi T., Ikeda T., Iba T., Eguchi Y., Okamoto K., Ogura H., Koseki K., Sakamoto Y., Takayama Y., Shirai K., Takasu O., Inoue Y., Mashiko K., Tsubota T., Endo S.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group for the JAAM DIC Antithrombin Trial (JAAMDICAT). A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013; 17 (6): 297. PMID: 24342495, PMCID:
21. PMC4057033. DOI: 10.1186/cc13163
22. Tagami T, Matsui H, Fushimi K, Yasunaga H. Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis. Thromb Haemost. 2015; 114 (3): 537–545. PMID: 25948492, DOI: 10.1160/TH15-01-0053
23. Rhodes A., Evans L.E., Alhazzani W., Levy M.M., Antonelli M., Ferrer R., Kumar A., Sevransky J.E., Sprung C.L., Nunnally M.E., Rochwerg B, Rubenfeld G.D., Angus D.C., Annane D., Beale R.J., Bellinghan G.J., Bernard G.R., Chiche J.D., Coopersmith C., De Backer D.P., French C.J., Fujishima S., Gerlach H., Hidalgo J.L., Hollenberg S.M., Jones A.E, Karnad D.R., Kleinpell R.M., Koh Y., Lisboa T.C., Machado F.R., Marini J.J., Marshall J.C., Mazuski J.E., McIntyre L.A., McLean A.S., Mehta S., Moreno R.P., Myburgh J, Navalesi P., Nishida O., Osborn T.M., Perner A., Plunkett C.M., Ranieri M., Schorr C.A., Seckel M.A., Seymour C.W., Shieh L., Shukri K.A., Simpson S.Q., Singer M., Thompson B.T., Townsend S.R., Van der Poll T., Vincent J.L., Wiersinga W.J., Zimmerman J.L., Dellinger R.P..Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. 2016. Intensive Care Med. 2017; 43: 304–377. PMID: 28101605, DOI: 10.1007/s00134-017-4683-6
24. Craft T. Key Questions in Anaesthesia. Bios Scientific 1993. Lincoln. United Kingdom. ISBN: 187274852X
25. Redkin I.V., Lopanin A.F., Skripkin Yu.V., Samojlov V.V., Lihvancev V.V. Determination of the antithrombin level allows predicting the clinical outcomes of sepsis. Vest. Anestesiol. Reanimatol. 2018; 15 (3) 41–46. [In Russ.]
26. ARDS Definition Task Force, Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., Fan E., Camporota L., Slutsky A.S. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307: 2526–2533. PMID: 22797452, DOI: 10.1001/jama.2012.5669
27. Moroz V.V., Marchenko D.N., Skripkin Y.V., Zabelina T.S., Ovezov A.M., Likhvantsev V.V. Perioperative Predictors of Unfavorable Outcome of Vascular Surgery. Obschaya Reanimatologiya=General Reanimatology. 2017; 13 (3): 6–12. [In Russ.]. DOI: 10.15360/1813-9779-2017-3-6-12.
28. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2: 1–1380. PMID: 23499048, DOI: 10.1053/j.ajkd.2013.02.349
29. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D.; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K., Alpert J.S., White H.D., Jaffe A.S., Katus H.A., Apple F.S., Lindahl B., Morrow D.A., Chaitman B.A., Clemmensen P.M., Johanson P., Hod H., Underwood R., Bax J.J., Bonow R.O., Pinto F., Gibbons R.J., Fox K.A., Atar D., Newby L.K., Galvani M., Hamm C.W., Uretsky B.F., Steg P.G., Wijns W., Bassand J.P., Menasché P., Ravkilde J., Ohman E.M., Antman E.M., Wallentin L.C., Armstrong P.W., Simoons M.L., Januzzi J.L., Nieminen M.S., Gheorghiade M., Filippatos G., Luepker R.V., Fortmann S.P., Rosamond W.D., Levy D., Wood D., Smith S.C., Hu D., Lopez-Sendon J.L., Robertson R.M., Weaver D., Tendera M., Bove A.A., Parkhomenko A.N., Vasilieva E.J., Mendis S.; ESC Committee for Practice Guidelines (CPG) Third universal definition of myocardial infarction Eur. Heart. J. 2012; 33: 2551–2567. PMID: 22922414, DOI: 10.1093/eurheartj/ehs184
30. Lihvancev V.V., Skripkin Yu.V., Filippovskaya Zh.S., Zhgulev D.A. Standardization of complications and outcomes of surgical treatment. Vest. Ahestesiol. Reanimatol. 2015; 12 (4): 53–66. [In Russ.]
31. National Surgical Quality Improvement Program. Chicago, IL: American College of Surgeons. Accessed 23 June 2014.2014; http: // acsnsqip.org.
32. Sabaté S., Mases A., Guilera N., Canet J., Castillo J., Orrego C., Sabaté A., Fita G., Parramón F., Paniagua P., Rodríguez A., Sabaté M.; ANESCARDIOCAT Group. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in noncardiac surgery. Br J Anaesth. 2011; 107: 879–890. PMID: 21890661. DOI: 10.1093/bja/aer268
33. Neely J.G., Karni R.J., Engel S.H., Fraley P.L., Nussenbaum B., Paniello R.C. Practical guides to understanding sample size and minimal clinically important difference (MCID). Otolaryngol. Head Neck Surg. 2007; 136 (1): 14–8. PMID: 17210326, DOI: 10.1016/j.otohns.2006.11.001
34. Gmurman V. E. Theory and mathematical statistics: studies. manual for University students. Moscow: Moscow. education, 2007. 478 [In Russ.].
35. Welty-Wolf K.E., Carraway M.S., Miller D.L., Ortel T.L., Ezban M., Ghio A.J., Idell S.; Piantadosi C.A. Coagulation blockade prevents sepsisinduced respiratory and renal failure in baboons. Am. J. Respir. Crit. Care Med. 2001; 164 (10,1): 1988–1996. PMID: 11734456
36. Sokratov N.V. Effect of antithrombin III on local hemostasis in the kidneys during experimental nephritis. Bull. Exp. Biol. Med. 2004; 138: 185–188. DOI: 10.1023/B: BEBM.0000048384.85774.c8
37. Ergin B., Kapucu A., Demirci-Tansel C., Ince C. The renal microcirculation in sepsis. Nephrol. Dial. Transplant. 2014; 30 (2): 169–177. PMID: 24848133, DOI: 10.1093/ndt/gfu105
38. Godin M., Murray P., Mehta R.L. Clinical approach to the patient with AKI and sepsis. Semin. Nephrol. 2015; 35: 12–22. PMID: 25795496, PMCID: PMC5617729, DOI: 10.1016/j.semnephrol.2015.01.003.
39. Alobaidi R., Basu R.K., Goldstein S.L., Bagshaw S.M. Sepsis-associated acute kidney injury. Semin. Nephrol. 2015; 35 (1): 2–11.PMID: 25795495, PMCID: PMC4507081, DOI: 10.1016/j.semnephrol.2015.01.002.
40. Fourrier F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., Marey A. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992. 101: 816–823. PMID: 1531791, DOI: 10.1378/chest.101.3.816.
41. Hack C.E. Tissue factor pathway of coagulation in sepsis. Crit. Care Med. Sep 2000; 9 (28): 25–30. PMID: 11007193, DOI: 10.1097/00003246-200009001-00006
Review
For citations:
Redkin I.V., Lopatin A.F., Yavorovskiy A.G., Likhvantsev V.V. Supplementation therapy with Antithrombin Drugs in the Combined Treatment of Sepsis. General Reanimatology. 2019;15(5):34-43. https://doi.org/10.15360/1813-9779-2019-5-34-43
Views:
1135
Email this article 